Boronic acids in medicinal chemistry: Anticancer, antibacterial and antiviral applications

Paul C. Trippier, Christopher McGuigan

Research output: Contribution to journalReview article

145 Citations (Scopus)

Abstract

In 2003, bortezomib, a first-in-class therapeutic, gained approval from the US Federal Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. Bortezomib contains a boronic acid, a functional group that has become increasingly more commonplace within the medicinal chemistry literature. The introduction of this drug has sparked a renewed interest in the investigation of boronic acids as drugs for a wide range of diseases. This review will guide the reader through the most recent developments in this field, by considering in turn, the biological target's amenable to the action of boronic acids.

Original languageEnglish (US)
Pages (from-to)183-198
Number of pages16
JournalMedChemComm
Volume1
Issue number3
DOIs
StatePublished - Sep 1 2010

Fingerprint

Boronic Acids
Pharmaceutical Chemistry
Antiviral Agents
Multiple Myeloma
Pharmaceutical Preparations
Mantle-Cell Lymphoma
Functional groups
Bortezomib
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

Boronic acids in medicinal chemistry : Anticancer, antibacterial and antiviral applications. / Trippier, Paul C.; McGuigan, Christopher.

In: MedChemComm, Vol. 1, No. 3, 01.09.2010, p. 183-198.

Research output: Contribution to journalReview article

@article{77eae5abb80343b0a23063a3b9d388c0,
title = "Boronic acids in medicinal chemistry: Anticancer, antibacterial and antiviral applications",
abstract = "In 2003, bortezomib, a first-in-class therapeutic, gained approval from the US Federal Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. Bortezomib contains a boronic acid, a functional group that has become increasingly more commonplace within the medicinal chemistry literature. The introduction of this drug has sparked a renewed interest in the investigation of boronic acids as drugs for a wide range of diseases. This review will guide the reader through the most recent developments in this field, by considering in turn, the biological target's amenable to the action of boronic acids.",
author = "Trippier, {Paul C.} and Christopher McGuigan",
year = "2010",
month = "9",
day = "1",
doi = "10.1039/c0md00119h",
language = "English (US)",
volume = "1",
pages = "183--198",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "3",

}

TY - JOUR

T1 - Boronic acids in medicinal chemistry

T2 - Anticancer, antibacterial and antiviral applications

AU - Trippier, Paul C.

AU - McGuigan, Christopher

PY - 2010/9/1

Y1 - 2010/9/1

N2 - In 2003, bortezomib, a first-in-class therapeutic, gained approval from the US Federal Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. Bortezomib contains a boronic acid, a functional group that has become increasingly more commonplace within the medicinal chemistry literature. The introduction of this drug has sparked a renewed interest in the investigation of boronic acids as drugs for a wide range of diseases. This review will guide the reader through the most recent developments in this field, by considering in turn, the biological target's amenable to the action of boronic acids.

AB - In 2003, bortezomib, a first-in-class therapeutic, gained approval from the US Federal Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma. Approval in the UK, for multiple myeloma, followed in 2006. Bortezomib contains a boronic acid, a functional group that has become increasingly more commonplace within the medicinal chemistry literature. The introduction of this drug has sparked a renewed interest in the investigation of boronic acids as drugs for a wide range of diseases. This review will guide the reader through the most recent developments in this field, by considering in turn, the biological target's amenable to the action of boronic acids.

UR - http://www.scopus.com/inward/record.url?scp=79952191452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952191452&partnerID=8YFLogxK

U2 - 10.1039/c0md00119h

DO - 10.1039/c0md00119h

M3 - Review article

AN - SCOPUS:79952191452

VL - 1

SP - 183

EP - 198

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 3

ER -